Clinical trial
StaphVAX in Cardiovascular Surgery Patients
NCT00211913 · Nabi Biopharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00211913 |
|---|---|
| Title | StaphVAX in Cardiovascular Surgery Patients |
| Official title | A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine, in Adult Patients Undergoing Cardiovascular Surgery |
| Lead sponsor | Nabi Biopharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Staphylococcal Infections, Cardiovascular Diseases, Cardiovascular Surgical Procedures |
| Intervention type | Biological |
| Interventions | S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate, placebo |
| Enrollment | 120 |
| Start date | Jun 1, 2004 |
| Primary completion | Oct 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Jan 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: